Indication |
For use in rheumatoid arthritis, preventing renal transplant rejection, Crohn's disease, and colitis. |
Pharmacodynamics |
Azathioprine is a chemotherapy drug, now rarely used for
chemotherapy but more for immunosuppression in organ transplantation and
autoimmune disease such as rheumatoid arthritis or inflammatory bowel
disease or Crohn's disease. It is a pro-drug, converted in the body to
the active metabolite 6-mercaptopurine. Azathioprine acts to inhibit
purine synthesis necessary for the proliferation of cells, especially
leukocytes and lymphocytes. It is a safe and effective drug used alone
in certain autoimmune diseases, or in combination with other
immunosuppressants in organ transplantation. Its most severe side effect
is bone marrow suppression, and it should not be given in conjunction
with purine analogues such as allopurinol. The enzyme thiopurine
S-methyltransferase (TPMT) deactivates 6-mercaptopurine. Genetic
polymorphisms of TPMT can lead to excessive drug toxicity, thus assay of
serum TPMT may be useful to prevent this complication. |
Mechanism of action |
Azathioprine antagonizes purine metabolism and may inhibit
synthesis of DNA, RNA, and proteins. It may also interfere with cellular
metabolism and inhibit mitosis. Its mechanism of action is likely due
to incorporation of thiopurine analogues into the DNA structure, causing
chain termination and cytotoxicity. |
Absorption |
Well absorbed following oral administration. |
Volume of distribution |
Not Available |
Protein binding |
Azathioprine and the metabolite mercaptopurine are moderately bound to serum proteins (30%). |
Metabolism |
Primarily converted to the active metabolites 6-mercaptopurine
and 6-thioinosinic acid via a non-enzymatica process. 6-mercaptopurine
is subsequently metabolized primarily by xanthine oxidase. |
Route of elimination |
Not Available |
Half life |
Approximately 5 hours for the unchanged drug and its metabolites. |
Clearance |
Not Available |
Toxicity |
The oral LD50 for single doses of azathioprine in mice
and rats are 2500 mg/kg and 400 mg/kg, respectively. Very large doses of
this antimetabolite may lead to marrow hypoplasia, bleeding, infection,
and death. |